Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT02928510 Terminated - Clinical trials for Recurrent Small Lymphocytic Lymphoma

Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma

Start date: February 1, 2016
Phase:
Study type: Observational

This research trial studies the mechanisms of idelalisib-associated diarrhea in patients with chronic lymphocytic leukemia, indolent non-hodgkin lymphoma, or small lymphocytic lymphoma that has come back after a period of improvement. The cancer treatment drug idelalisib triggers diarrhea in some patients. Studying stool, blood, and tissue samples in the lab from patients who are given idelalisib may help doctors learn more about the side effects and may help to treat them in future patients.

NCT ID: NCT02927964 Completed - Clinical trials for Mantle Cell Lymphoma

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

Start date: November 7, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial studies the side effects and best dose of toll-like receptor 9 (TLR9) agonist SD-101 when given together with ibrutinib and radiation therapy and to see how well they work in treating patients with Low Grade Follicular Lymphoma, Marginal Zone Lymphoma, or Mantle Cell Lymphoma that has come back after a period of improvement or no longer responds to treatment. Immunostimulants such as TLR9 agonist SD-101 may increase the ability of the immune system to fight infection and disease. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving TLR9 agonist SD-101 with ibrutinib and radiation therapy may induce an immune response and prolong anti-tumor response.

NCT ID: NCT02927925 Completed - Lymphoma Clinical Trials

A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type

Start date: February 14, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the clinical efficacy and safety of daratumumab in relapsed or refractory natural killer/T-cell lymphomas (NKTCL).

NCT ID: NCT02927756 Recruiting - Clinical trials for Non-Hodgkin Lymphoma Transformed Recurrent

Italian Multicenter Retrospective Observational Study on Transformed Lymphomas

FLT-Oss-2015
Start date: November 2017
Phase: N/A
Study type: Observational

Study purpose is to evaluate treatment outcome and survival in patient with aggressive lymphomas transformed from Follicular Lymphoma.

NCT ID: NCT02927717 Not yet recruiting - Clinical trials for Grade 3b Follicular Lymphoma

An Italian Experience on Grade 3b Follicular Lymphoma

FL3b-Oss-2015
Start date: October 2016
Phase: N/A
Study type: Observational

Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma. Also an histological central review is planned in order to re-assess baseline diagnosis according to new 2016 World Health Organization (WHO) criteria.

NCT ID: NCT02926833 Completed - Clinical trials for Refractory Diffuse Large B Cell Lymphoma

Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

ZUMA-6
Start date: September 29, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab combination regimens. The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as measured by complete response rate in participants with refractory diffuse large B-cell lymphoma (DLBCL). Participants who received an infusion of KTE-C19 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968 (NCT05041309).

NCT ID: NCT02924402 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Start date: October 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).

NCT ID: NCT02924272 Active, not recruiting - Multiple Myeloma Clinical Trials

Ixazomib Rollover Study

Start date: December 16, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.

NCT ID: NCT02920697 Completed - Clinical trials for Multiple Myeloma (MM)

Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

Start date: March 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety profile and tolerability of S 55746 in patients with CLL, B-Cell NHL and MM, in terms of Dose-Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD) and determine the Recommended Phase 2 Dose (RP2D) through safety profile (DLT, MTD), PK profile, PD profile and preliminary efficacy.

NCT ID: NCT02919670 Completed - Multiple Myeloma Clinical Trials

A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma

Start date: October 2016
Phase: N/A
Study type: Interventional

This research study is evaluating Enterade, a supplement, as a possible treatment for the side effects caused by Stem Cell Transplant. The following interventions will be involved in this study: - Enterade plus standard supportive care - Placebo plus standard supportive care. The placebo will be a mixture of water, electrolytes, and sweetener.